Skip to main content

Table 5 Summary of most frequent on-treatment AEs and serious AEs (safety population)

From: Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study

  FF 100 μg FF 200 μg
  (N = 119) (N = 119)
AEs   
On-treatment 70 (59) 75 (63)
On-treatment, treatment-related* 1 (< 1) 6 (5)
On-treatment, leading to withdrawal 2 (2) 2 (2)
Serious AEs   
On-treatment 3 (3) 4 (3)
On-treatment AEs occurring in ≥ 5% patients in either treatment group   
Nasopharyngitis 14 (12) 15 (13)
Headache 12 (10) 15 (13)
Bronchitis 14 (12) 8 (7)
Influenza 5 (4) 8 (7)
Sinusitis 8 (7) 5 (4)
Pharyngitis 7 (6) 4 (3)
Upper respiratory tract infection 2 (2) 7 (6)
  1. All data are n (%).
  2. *AEs deemed treatment-related by the investigator prior to unblinding.
  3. AE = adverse event; FF = fluticasone furoate.